Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics

Fulcrum Therapeutics, Inc. (FULC): $4.00

0.09 (-2.20%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add FULC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#172 of 356

in industry

FULC Price/Volume Stats

Current price $4.00 52-week high $15.00
Prev. close $4.09 52-week low $2.25
Day low $3.97 Volume 50,803
Day high $4.07 Avg. volume 1,420,253
50-day MA $4.56 Dividend yield N/A
200-day MA $5.45 Market Cap 247.29M

FULC Stock Price Chart Interactive Chart >

FULC POWR Grades

  • Sentiment is the dimension where FULC ranks best; there it ranks ahead of 79.85% of US stocks.
  • The strongest trend for FULC is in Value, which has been heading down over the past 177 days.
  • FULC's current lowest rank is in the Stability metric (where it is better than 3.06% of US stocks).

FULC Stock Summary

  • FULC's price/sales ratio is 84.72; that's higher than the P/S ratio of 97.62% of US stocks.
  • Revenue growth over the past 12 months for FULCRUM THERAPEUTICS INC comes in at -78.97%, a number that bests merely 2.25% of the US stocks we're tracking.
  • In terms of volatility of its share price, FULC is more volatile than 95.6% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to FULCRUM THERAPEUTICS INC, a group of peers worth examining would be ADVM, SPRO, DCPH, BPMC, and YMAB.
  • FULC's SEC filings can be seen here. And to visit FULCRUM THERAPEUTICS INC's official web site, go to www.fulcrumtx.com.

FULC Valuation Summary

  • FULC's price/earnings ratio is -2.6; this is 109.74% lower than that of the median Healthcare stock.
  • Over the past 51 months, FULC's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for FULC.

Stock Date P/S P/B P/E EV/EBIT
FULC 2023-09-22 84.7 0.9 -2.6 -2.4
FULC 2023-09-21 83.1 0.9 -2.6 -2.3
FULC 2023-09-20 90.0 1.0 -2.8 -2.5
FULC 2023-09-19 87.6 1.0 -2.7 -2.5
FULC 2023-09-18 88.6 1.0 -2.7 -2.5
FULC 2023-09-15 91.2 1.0 -2.8 -2.6

FULC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FULC has a Quality Grade of D, ranking ahead of 14.4% of graded US stocks.
  • FULC's asset turnover comes in at 0.108 -- ranking 260th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FULC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.108 1 -1.792
2021-03-31 0.090 1 -1.731
2020-12-31 0.069 1 -1.552
2020-09-30 0.037 1 -2.003
2020-06-30 0.024 1 -2.355
2020-03-31 0.008 1 -3.830

FULC Price Target

For more insight on analysts targets of FULC, see our FULC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.86 Average Broker Recommendation 1.5 (Moderate Buy)

Fulcrum Therapeutics, Inc. (FULC) Company Bio


Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


FULC Latest News Stream


Event/Time News Detail
Loading, please wait...

FULC Latest Social Stream


Loading social stream, please wait...

View Full FULC Social Stream

Latest FULC News From Around the Web

Below are the latest news stories about FULCRUM THERAPEUTICS INC that investors may wish to consider to help them evaluate FULC as an investment opportunity.

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference, being held in New York, NY on Thursday, September 28, 2023 at 8:35 a.m. ET. The webcast of the presentation will be accessible here and through the Invest

Yahoo | September 22, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement mater

Yahoo | September 15, 2023

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Enrolled 260 patients; topline data expected in the fourth quarter of 2024CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe. “We are very pleased to

Yahoo | September 7, 2023

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | August 25, 2023

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Yahoo | August 24, 2023

Read More 'FULC' Stories Here

FULC Price Returns

1-mo -30.07%
3-mo 18.69%
6-mo 68.07%
1-year -50.98%
3-year -48.98%
5-year N/A
YTD -45.05%
2022 -58.85%
2021 51.07%
2020 -29.63%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!